Martin Akerman
Dr. Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a post doctorate fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.
Kenny Carberry
Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers a wide array of indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.
Christopher Rao
Christopher has 15 years of experience in clinical research, with a focus on clinical trial design and operations. As a strategist, Christopher works identifies client’s key needs early and creates tailored, targeted plans for clinical development and market success. Throughout his career, Christopher has worked closely with small-to-medium biotech and pharmaceutical oncology companies, developing novel technologies.
Ibraheem Badejo
Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.
From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.
During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.
Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending
Alexandra Moulson
Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.
She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.
Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.
Nicolas Pourbaix
Nezar Akeel
Nezar is a former Division I soccer player and engineer who combined his passion for fitness and engineering to develop the MAXPRO connected gym and to help make fitness more fun and accessible. While he spent most of his career in the auto industry running organizations and leading companies in the US, Asia, and Africa, he never abandoned his 16-year long-held idea to develop a truly portable all-in-one gym that you can use anywhere. After years of self-funded development, he created the MAXPRO. An award-winning connected cable gym that provides 5lbs to 300lbs of resistance in a 9lbs package. Now MAXPRO along with the MAXPRO Coaching App is being used by over 20,000 customers worldwide, and MAXPRO is set to develop into a global lifestyle brand driven by its passionate global community.
Mike Telem
Mike is the Co-founder and Chief Business Officer at Kemtai focusing on strategic business development and B2B deals. He is a serial entrepreneur with experience in building and marketing digital products. Mike was previously VP of Product Innovation and Product Marketing at Marketo which he joined Marketo following the acquisition of Insightera, the startup he co-founded in 2009 which provided a real-time web personalization SaaS for global businesses.
Dan Fradin
Dan Fradin is the Founder and CEO of Impact Wrap, the world's leading platform for connected heavy bag fitness. In 2017, he brought together decades of experience from martial arts, fitness, technology, and marketing to bootstrap his Philly-based SaaS and hardware company.
Impact Wrap combines US-made on-bag sensors and cloud-based software to deliver real-time fitness metrics across any type of strike on almost any bag.
With over 1.2M workouts and almost 160K classes in 190 gyms, Impact Wrap has grown organically by concentrating on making the best possible product for members, staff, and owners.
2022 will be our breakout year as we leverage our global network of content creators to launch Impact@Home, an innovative hybrid gym-to-home model.